We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+2.84%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.32B
AUM Growth
-$616M
Cap. Flow
-$442M
Cap. Flow %
-13.32%
Top 10 Hldgs %
35.56%
Holding
123
New
10
Increased
41
Reduced
28
Closed
11

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$31.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$25.3M
3
GPCR icon
Structure Therapeutics
GPCR
+$24.1M
4
UNH icon
UnitedHealth
UNH
+$22.1M
5
LLY icon
Eli Lilly
LLY
+$14.6M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$99.4M
2
PEN icon
Penumbra
PEN
+$47.9M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$44M
4
BSX icon
Boston Scientific
BSX
+$30.4M
5
IDXX icon
Idexx Laboratories
IDXX
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 97.3%
2 Consumer Staples 1.87%
3 Industrials 0.25%
4 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEN icon
101
Compugen
CGEN
$222M
$1.66M 0.05%
989,990
-300,000
-23% -$625K
SPRB
102
Spruce Biosciences
SPRB
$126M
$1.35M 0.04%
34,788
– –
KYTX icon
103
Kyverna Therapeutics
KYTX
$489M
$1.34M 0.04%
178,963
– –
KRRO icon
104
Korro Bio
KRRO
$201M
$1.21M 0.04%
+35,719
New +$1.97M
ALLK
105
DELISTED
Allakos
ALLK
$1.2M 0.04%
+1,200,409
New +$1.43M
BMEA icon
106
Biomea Fusion
BMEA
$91.3M
$815K 0.02%
181,147
– –
VINC
107
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$722K 0.02%
44,586
– –
TLPH icon
108
Talphera
TLPH
$73.2M
$282K 0.01%
316,460
– –
NUVB.WS
109
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$21.4K ﹤0.01%
134,028
– –
ALNY icon
110
CALL
Alnylam Pharmaceuticals
ALNY
$29.2B
– –
-32,500
Closed -$4.86M
AMLX icon
111
Amylyx Pharmaceuticals
AMLX
$2.47B
– –
-1,011,412
Closed -$2.87M
CGON icon
112
CG Oncology
CGON
$6.64B
– –
-170,859
Closed -$7.5M
COLL icon
113
Collegium Pharmaceutical
COLL
$890M
– –
-562,000
Closed -$21.8M
IMTX icon
114
Immatics
IMTX
$1.33B
– –
-848,751
Closed -$8.92M
IRON icon
115
Disc Medicine
IRON
$2.98B
– –
-363,468
Closed -$22.6M
SGRY icon
116
Surgery Partners
SGRY
$1.99B
– –
-985,000
Closed -$29.4M
VKTX icon
117
Viking Therapeutics
VKTX
$4B
– –
-261,000
Closed -$21.4M
OKUR
118
OnKure Therapeutics
OKUR
$163M
– –
-75,173
Closed -$1.25M
CERE
119
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-547,946
Closed -$23.2M
SWAV
120
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-135,000
Closed -$44M
1 2 3 4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Rock Springs Capital Management held 123 positions worth $3.32B, down 16% from $3.94B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $442M in Q2 2024, closing 11 positions and reducing 28 holdings. Its most notable exit was Shockwave Medical, Inc. Common Stock, an estimated $44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Insmed worth $54.2M.

  • Rock Springs Capital Management's largest Q2 2024 buy was Insmed: 808,356 shares worth $54.2M.
  • Rock Springs Capital Management added most to Structure Therapeutics in Q2 2024, an estimated $24.1M increase.
  • Rock Springs Capital Management's biggest Q2 2024 reduction was Immunocore, cutting an estimated $99.4M.
  • Rock Springs Capital Management fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $44M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $3.32B portfolio in Q2 2024.
  • Rock Springs Capital Management opened 10 new positions and closed 11 in Q2 2024.
  • Rock Springs Capital Management's portfolio value fell 16% quarter-over-quarter to $3.32B.

Based on Rock Springs Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.